Peptide purity explained
What HPLC purity numbers actually measure, what the impurities tend to be, and how to interpret 95%, 98%, and 99% claims on peptide COAs.
Updated May 7, 2026 · 5 min read
Peptide purity is one of the most quoted numbers in research-chem marketing and one of the least understood. A vial labeled "99% pure" sounds essentially the same as "98% pure," but the gap between them — and the gap between either of those and 95% — has a real impact on what's actually in the vial and how it behaves in the body. This page covers what HPLC purity actually measures, what the remaining percent tends to be, and how to interpret claims meaningfully.
What HPLC purity measures
High-performance liquid chromatography (HPLC) is the standard analytical method for peptide purity. In a reverse-phase HPLC run, the peptide and any impurities are separated based on their interaction with the column. The detector — typically UV absorbance at 214 nm or 220 nm — produces a chromatogram showing peaks over time.
Purity is reported as the percentage of total peak area attributable to the main (target) peak:
- A single tall peak with a flat baseline = high purity
- Multiple peaks with comparable area = significant impurities
- Small "shoulders" off the main peak = closely-related impurities (often deletion sequences, oxidation products)
The number you see on a COA — "99.2% by HPLC at 214 nm" — is shorthand for "99.2% of the area under the chromatogram came from the main peak."
What the other 1 to 5% actually is
The non-main-peak material in a peptide vial is usually one of:
| Impurity type | Description | Risk level |
|---|---|---|
| Deletion sequences | Peptide variants missing one or more amino acids | Variable; often biologically active |
| Truncation products | Peptide variants stopped early | Variable |
| Oxidation products | Methionine, tryptophan, cysteine residues oxidized | Generally low risk |
| Diastereomers | Same sequence, wrong stereochemistry at one residue | Variable |
| Synthesis byproducts | Protecting groups, scavengers, residual reagents | Generally low risk |
| Solvents and counterions | Acetate, TFA, residual solvents | Low risk in normal amounts |
| Water content | Residual moisture | Low risk |
The thing to internalize is that "impurity" doesn't necessarily mean "inert filler." Many impurities are related peptides that may have their own biological activity — sometimes weaker than the target, sometimes different, sometimes contributing to side effects.
How to interpret common purity ranges
| Purity claim | Interpretation | When you'd see it |
|---|---|---|
| 99.5%+ | Pharmaceutical-grade target | Good vendors, careful production |
| 98 to 99% | Acceptable, common | Reputable research-chem vendors |
| 95 to 98% | Marginal | Lower-tier research-chem |
| 90 to 95% | Problematic | Avoid for injectable use |
| Below 90% | Unsuitable | Avoid |
| Not stated | Unknown | Treat as low |
The 99-vs-98 difference matters less than 99-vs-95. Going from 95% to 98% halves the impurity load; going from 98% to 99% halves it again. Both are meaningful.
Why purity matters more than it first appears
A 5% impurity load in a peptide vial often translates to a meaningful biological signal because:
- Many peptide impurities are related sequences with their own activity
- Injection bypasses the GI tract's filtering, so impurities reach circulation directly
- Cumulative dosing means impurity load accumulates over a cycle
- Side effect attribution falls on the labeled peptide, not the impurities
A user reporting "BPC-157 gave me unusual fatigue" may be reacting to the 3 to 5% non-BPC-157 material in a 95% pure vial — not BPC-157 itself. Higher purity is genuinely meaningful, not just marketing.
Pharmaceutical-grade vs research-chem-grade
Pharmaceutical manufacturing aims for tight specifications across multiple attributes. Research-chem production is much more variable. The differences:
| Attribute | Pharmaceutical-grade | Research-chem-grade |
|---|---|---|
| Purity target | 99.5%+ typical | 98% typical, varies down |
| Impurity profile | Characterized and within limits | Often unspecified |
| Endotoxin limit | Below 0.5 EU/mg | Below 5 EU/mg (community-accepted) |
| Manufacturing standard | cGMP | Variable |
| Batch consistency | Tight | Variable |
| Documentation | Comprehensive | COA-only at best |
The research-chem market spans a wide range. The best research-chem vendors approach pharmaceutical specifications; the worst are dramatically below.
How to verify purity claims
Three steps:
- Look at the actual COA, not the marketing claim. "99% pure" on a product page without a backing COA is a marketing number.
- Look at the chromatogram, not just the percentage. A clean main peak with a flat baseline is what you want.
- Check the wavelength. Most peptides are quantified at 214 nm or 220 nm, where peptide bonds absorb. Unusual wavelengths can produce inflated purity numbers.
For a step-by-step on what to look for in the COA, see how to read a COA.
Purity claims and side effect investigation
When a side effect appears unexpectedly, purity is one of two main quality-related explanations (the other is endotoxin). The investigation order:
- Check the COA for the specific batch — purity AND endotoxin numbers
- If purity is below 98%, that may be contributing
- If endotoxin is high, that's likely contributing more
- If both look clean and the side effect persists, look elsewhere — dosing, stacking, individual response
For more on the endotoxin side, see endotoxin testing explained.
The bottom line
Purity numbers are real and matter, but they're not the only quality variable. A 99% pure vial with high endotoxin can produce worse side effects than a 97% pure vial with clean endotoxin testing. Read the whole COA, not just the headline number, and weight purity, endotoxin, and identity together when evaluating a batch.